Natural Human Plasmacytoid Dendritic Cells Induce Antigen-Specific T-Cell Responses in Melanoma Patients
about
Exploiting the Immunogenic Potential of Cancer Cells for Improved Dendritic Cell VaccinesDendritic Cells in Oncolytic Virus-Based Anti-Cancer TherapyDendritic Cell Therapy in an Allogeneic-Hematopoietic Cell Transplantation Setting: An Effective Strategy toward Better Disease Control?Investigating Evolutionary Conservation of Dendritic Cell Subset Identity and FunctionsUnderstanding dendritic cells and their role in cutaneous carcinoma and cancer immunotherapyPros and Cons of Antigen-Presenting Cell Targeted Tumor VaccinesThe plasmacytoid dendritic cell as the Swiss army knife of the immune system: molecular regulation of its multifaceted functionsDendritic Cell-Based Cancer Immunotherapy against Multiple Myeloma: From Bench to ClinicRationale for a Multimodality Strategy to Enhance the Efficacy of Dendritic Cell-Based Cancer Immunotherapy.The dark side of dendritic cells: development and exploitation of tolerogenic activity that favor tumor outgrowth and immune escape.Dendritic-cell-based therapeutic cancer vaccinesSingle-cell RNA-seq reveals new types of human blood dendritic cells, monocytes, and progenitors.Optimizing dendritic cell-based approaches for cancer immunotherapyClinical Implications of Co-Inhibitory Molecule Expression in the Tumor Microenvironment for DC Vaccination: A Game of Stop and Go.Dendritic Cell-Based Vaccines that Utilize Myeloid Rather than Plasmacytoid Cells Offer a Superior Survival Advantage in Malignant Glioma.Generation of a cord blood-derived Wilms Tumor 1 dendritic cell vaccine for AML patients treated with allogeneic cord blood transplantation.The multifaceted biology of plasmacytoid dendritic cells.Immune-related Adverse Events of Dendritic Cell Vaccination Correlate With Immunologic and Clinical Outcome in Stage III and IV Melanoma Patients.CMRF-56(+) blood dendritic cells loaded with mRNA induce effective antigen-specific cytotoxic T-lymphocyte responses.A short-term increase of the postoperative naturally circulating dendritic cells subsets in flurbiprofen-treated patients with esophageal carcinoma undergoing thoracic surgery.Ipilimumab administered to metastatic melanoma patients who progressed after dendritic cell vaccination.Dendritic cell-based immunotherapy for myeloid leukemias.Antigen cross-presentation of immune complexes.Harnessing RNA sequencing for global, unbiased evaluation of two new adjuvants for dendritic-cell immunotherapy.Costimulatory molecules on immunogenic versus tolerogenic human dendritic cells.Human dendritic cell subsets in vaccination.Exploiting dendritic cells in the development of cancer vaccines.Human plasmacytoid dendritic cells: from molecules to intercellular communication networkRecent progress in peptide vaccination in cancer with a focus on non-small-cell lung cancer.Type I Interferons as Stimulators of DC-Mediated Cross-Priming: Impact on Anti-Tumor Response.Dendritic cell-based approaches in the fight against diseases.Crosstalk between dendritic cell subsets and implications for dendritic cell-based anticancer immunotherapy.Paradigm Shift in Dendritic Cell-Based Immunotherapy: From in vitro Generated Monocyte-Derived DCs to Naturally Circulating DC Subsets.Antitumor Virotherapy by Attenuated Measles Virus (MV).Targeting human dendritic cells in situ to improve vaccines.mRNA-based dendritic cell vaccines.The immune escape in melanoma: role of the impaired dendritic cell function.The ReNAissanCe of mRNA-based cancer therapy.Designing effective vaccines for colorectal cancer.Dendritic cell-based vaccine research against cancer.
P2860
Q26772715-455E8B8D-96E4-4F5B-B85B-5D438830A485Q26774345-D08562F9-9247-4C77-8A79-B4D9D2885CD8Q26830857-20405FAA-A0DC-4139-B4E0-C648F26CCAF2Q26995456-C785BCD9-6FA2-45D2-920F-84D91E69A230Q27004702-93A8E4AE-F289-4926-81CD-2B3A95C2A235Q27013679-F793F2CC-59AB-4065-84E4-934065EA262AQ27023380-1F103616-8FF4-4EF9-9F43-2E8B57FA2277Q27023621-AC18E4AD-B0B3-4673-80CC-1C445126B28BQ27686800-E0E4B73C-D75D-432A-808E-722D49B53AB8Q30317628-D42DC6B9-ED40-4E15-91A2-CECCC3F5F955Q34360094-E19D32E2-CA79-495E-A737-B7330A3DD1BFQ34555562-148A16D7-5BE7-47D1-822F-CBCBF3811B37Q34637535-4AAEA026-D288-48C7-85FA-1F69571DD193Q34658452-C1A7D0B7-9A2F-432C-87DB-F0BB8822348FQ35763478-3C43987D-4AA0-409F-9B69-EBC7169C08B9Q36107961-F4A9CEC6-CE74-4346-98C5-376446C36B92Q36731249-E7D1678F-7C0B-4829-97ED-7B0C952C79F9Q36992766-70E431F3-6EFF-4D44-879D-83867800A077Q37078990-74CD085E-605E-4787-BC96-7C33DD3CFE25Q37109852-3F9EE320-0386-4574-82BC-18A1731805BBQ37224609-5CAD3036-5308-46E5-8ED5-2D8305876478Q37420778-D9490851-340B-496A-BB47-0925DD0510A8Q37689507-ED36A66A-C791-40C6-807B-D9DE9C095155Q37746179-77C36924-218B-410A-A50A-612270779D52Q38097034-26824AE0-B467-46AF-B33B-BEBB56AAF80DQ38110971-02E26C75-F580-4094-AC89-E27478E9E234Q38148774-DFBD1792-112E-4B60-BEB6-B359822A63F2Q38166716-ADBDC3B1-C265-4FB1-B4D6-CFFC3DFD3D6BQ38168904-2EF2DEE0-B33D-42D4-BFD4-E6DAD7A11EBCQ38176613-F08C87AD-A281-45CF-97E5-302B898F16F3Q38195040-1DB0634E-1169-4B34-891C-C3BEC5BBB4AAQ38206571-9DC98818-50C6-4FC3-A031-AAF818D9E5CAQ38208309-5205C8B3-7E79-48EC-9305-2199244803E8Q38212137-E962FDD7-77D2-401E-8DC6-D65D92399BF6Q38235001-0473BB7A-5552-486C-8C18-7199666392FEQ38246769-B79E69F5-6308-4E8E-A893-3052D6FF699FQ38250071-92F44DE9-CE18-4515-8D47-89689052703EQ38255012-C5F07FE6-9893-4AD1-9C35-0B22DAC2B9BCQ38260051-CF8D553A-9397-4EC0-A37A-2E5D2F0467EDQ38281782-6EADAB36-A04F-41CA-87D1-FEAA05C301FE
P2860
Natural Human Plasmacytoid Dendritic Cells Induce Antigen-Specific T-Cell Responses in Melanoma Patients
description
article
@en
im Januar 2013 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована в січні 2013
@uk
name
Natural Human Plasmacytoid Den ...... Responses in Melanoma Patients
@en
Natural Human Plasmacytoid Den ...... Responses in Melanoma Patients
@nl
type
label
Natural Human Plasmacytoid Den ...... Responses in Melanoma Patients
@en
Natural Human Plasmacytoid Den ...... Responses in Melanoma Patients
@nl
prefLabel
Natural Human Plasmacytoid Den ...... Responses in Melanoma Patients
@en
Natural Human Plasmacytoid Den ...... Responses in Melanoma Patients
@nl
P2093
P50
P1433
P1476
Natural human plasmacytoid den ...... responses in melanoma patients
@en
P2093
Barbara M Schulte
Cornelis J A Punt
Daniel Benitez-Ribas
Erik H J G Aarntzen
Gregor Winkels
Michelle van Rossum
Otto C Boerman
Pierre G Coulie
Sandra Croockewit
Tetsuro Baba
P304
P356
10.1158/0008-5472.CAN-12-2583
P407
P577
2013-01-23T00:00:00Z